AMCZX
Price
$19.49
Change
+$0.04 (+0.21%)
Updated
Jul 31 closing price
Net Assets
294.35M
VMGIX
Price
$116.25
Change
+$0.23 (+0.20%)
Updated
Jul 31 closing price
Net Assets
34.8B
Interact to see
Advertisement

AMCZX vs VMGIX

AMCZX vs VMGIX Comparison Chart in %
View a ticker or compare two or three
VS
AMCZX vs. VMGIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMCZX is a Buy and VMGIX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VMGIX has more cash in the bank: 34.8B vs. AMCZX (294M). VMGIX pays higher dividends than AMCZX: VMGIX (0.49) vs AMCZX (0.00). AMCZX was incepted earlier than VMGIX: AMCZX (11 years) vs VMGIX (20 years). AMCZX (0.92) is less costly to investors than VMGIX (0.19). AMCZX is a more actively managed with annual turnover of: 88.64 vs. VMGIX (17.00). VMGIX has a lower initial minimum investment than AMCZX: VMGIX (3000) vs AMCZX (500000). AMCZX annual gain was more profitable for investors over the last year : 8.16 vs. VMGIX (1.61). VMGIX return over 5 years is better than : 23.08 vs. AMCZX (-14.65).
AMCZXVMGIXAMCZX / VMGIX
Total Expense Ratio0.790.19416%
Annual Report Gross Expense Ratio0.920.19484%
Fund Existence11 years20 years-
Gain YTD4.1695.93670%
Front LoadN/AN/A-
Min. Initial Investment500000300016,667%
Min. Initial Investment IRAN/AN/A-
Net Assets294M34.8B1%
Annual Yield % from dividends0.000.49-
Returns for 1 year8.161.61507%
Returns for 3 years49.4639.77124%
Returns for 5 years-14.6523.08-63%
Returns for 10 years90.04183.4949%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ESGV132.020.89
+0.68%
Vanguard ESG US Stock ETF
SPMV50.75N/A
N/A
Invesco S&P 500 Minimum Variance ETF
BNDP73.11-0.17
-0.23%
Vanguard Core-Plus Bond Index ETF
NIM9.16-0.03
-0.33%
Nuveen Select Maturities Municipal Fund
HQL19.10-0.34
-1.75%
abrdn Life Sciences Investors